New classifications and pathophysiology of the inflammatory myopathies;Nouvelles classifications et physiopathologie des myopathies inflammatoires

Revue de Medecine Interne

Volumn 28, Issue 9, 2007, Pages 603-612

  Benveniste, O ^a   Dubourg, O ^a   Herson, S ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Auto antibobies; Dermatomyositis; Inclusion body myositis; Overlap myositis; Pathogenesis; Polymyositis

Indexed keywords

CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DEGENERATIVE DISEASE; DERMATOMYOSITIS; DISEASE CLASSIFICATION; HISTOLOGY; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATORY INFILTRATE; ISCHEMIA; MICROANGIOPATHY; MOLECULAR MECHANICS; MUSCLE CELL; MYOPATHY; MYOSITIS; NERVE FIBER; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMYOSITIS; PROGNOSIS; SHORT SURVEY; CLASSIFICATION; PATHOLOGY; REVIEW;

DERMATOMYOSITIS; HUMANS; MYOSITIS; POLYMYOSITIS;

EID: 34548142652     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.03.004     Document Type: Short Survey

References (55)

1. Hoogendijk J.E., Amato A.A., Lecky B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14 (2004) 337-345
2. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., and Senecal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84 (2005) 231-249
3. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292 (1975) 344-347
4. Love L.A., Leff R.L., Fraser D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70 (1991) 360-374
5. Medsger Jr. T.A., and Oddis C.V. Classification and diagnostic criteria for polymyositis and dermatomyositis. J. Rheumatol. 22 (1995) 581-585
6. Van der Meulen M.F., Bronner I.M., Hoogendijk J.E., et al. Polymyositis: an overdiagnosed entity. Neurology 61 (2003) 316-321
7. Kissel J.T. Misunderstandings, misperceptions, and mistakes in the management of the inflammatory myopathies. Semin. Neurol. 22 (2002) 41-51
8. Hilton-Jones D. Inflammatory muscle diseases. Curr. Opin. Neurol. 14 (2001) 591-596
9. Cosnes A., Amaudric F., Gherardi R., et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch. Dermatol. 131 (1995) 1381-1385
10. Reed A.M., and Ytterberg S.R. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 28 (2002) 891-916
11. Chinoy H., Salway F., Fertig N., et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res. Ther. 8 (2005) R13
12. Werth V.P., Berlin J.A., Callen J.P., Mick R., and Sullivan K.E. Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J. Invest. Dermatol. 119 (2002) 1394-1399
13. Werth V.P., Callen J.P., Ang G., and Sullivan K.E. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J. Invest. Dermatol. 119 (2002) 617-620
14. Engel A.G., and Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum. Pathol. 17 (1986) 704-721
15. Banker B.Q. Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels. J. Neuropathol. Exp. Neurol. 34 (1975) 46-75
16. Kissel J.T., Mendell J.R., and Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314 (1986) 329-334
17. Roebker J.J., Case J.D., Lear S.C., Hodge S.J., and Callen J.P. Immunoperoxidase technique on paraffin sections fails to demonstrate immunoglobulin deposition in cutaneous lesions from patients with dermatomyositis. Am. J. Dermatopathol. 10 (1988) 297-299
18. Meyer O., Kaiser P., Haim T., et al. Anti-vascular endothelial cell antibodies (AECA): comparison of two assay methods and clinical applications. Rev. Rhum. Engl. Ed 62 (1995) 737-747
19. Greenberg S.A., Pinkus J.L., Pinkus G.S., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57 (2005) 664-678
20. Targoff I.N., and Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28 (1985) 796-803
21. Ghirardello A., Zampieri S., Iaccarino L., et al. Anti-Mi-2 antibodies. Autoimmunity 38 (2005) 79-83
22. Roux S., Seelig H.P., and Meyer O. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J. Rheumatol. 25 (1998) 395-396
23. Sato S., Hirakata M., Kuwana M., et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52 (2005) 1571-1576
24. Figarella-Branger D., Lacroix C., Coquet M., Gherardi R., and Pellissier J.F. Myopathies inflammatoires idiopathiques. Ann. Pathol. 21 (2001) 279-284
25. Emslie-Smith A.M., and Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27 (1990) 343-356
26. De Bleecker J.L., De Paepe B., Vanwalleghem I.E., and Schroder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 58 (2002) 1779-1785
27. Sallum A.M., Marie S.K., Wakamatsu A., et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J. Rheumatol. 31 (2004) 801-807
28. Benveniste O., Cherin P., Maisonobe T., et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J. Immunol. 167 (2001) 3521-3529
29. Benveniste O., Herson S., Salomon B., et al. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann. Neurol. 56 (2004) 867-872
30. Shamim E.A., Rider L.G., and Miller F.W. Update on the genetics of the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 12 (2000) 482-491
31. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325 (1991) 1487-1498
32. De Bleecker J.L., and Engel A.G. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am. J. Pathol. 146 (1995) 1178-1187
33. Nagaraju K., Raben N., Loeffler L., et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl. Acad. Sci. USA 97 (2000) 9209-9214
34. Hohlfeld R., and Engel A.G. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann. Neurol. 29 (1991) 498-507
35. Arahata K., and Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann. Neurol. 19 (1986) 112-125
36. Goebels N., Michaelis D., Engelhardt M., et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J. Clin. Invest. 97 (1996) 2905-2910
37. Schneider C., Gold R., Dalakas M.C., et al. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J. Neuropathol. Exp. Neurol. 55 (1996) 1205-1209
38. Nishio J., Suzuki M., Miyasaka N., and Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J. Immunol. 167 (2001) 4051-4058
39. Askanas V., and Engel W.K. Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr. Opin. Neurol. 15 (2002) 525-531
40. Yunis E.J., and Samaha F.J. Inclusion body myositis. Lab. Invest. 25 (1971) 240-248
41. Badrising U.A., Maat-Schieman M., Van Duinen S.G., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55 (2000) 1385-1387
42. Badrising U.A., Schreuder G.M., Giphart M.J., et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63 (2004) 2396-2398
43. Querfurth H.W., Suhara T., Rosen K.M., et al. Beta-amyloid peptide expression is sufficient for myotube death: implications for human inclusion body myopathy. Mol. Cell. Neurosci. 17 (2001) 793-810
44. Dimitri D., Benveniste O., Dubourg O., et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 129 (2006) 986-995
45. Amemiya K., Granger R.P., and Dalakas M.C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123 (2000) 2030-2039
46. Nagaraju K., Casciola-Rosen L., Lundberg I., et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52 (2005) 1824-1835
47. Koffman B.M., Rugiero M., and Dalakas M.C. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21 (1998) 115-117
48. Dimitri D., Andre C., Roucoules J., Hosseini H., Humbel R.L., and Authier F.J. Myopathy associated with anti-signal recognition peptide antibodies: Clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 35 (2007) 389-395
49. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
50. Miller T., Al-Lozi M.T., Lopate G., and Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J. Neurol. Neurosurg. Psychiatry 73 (2002) 420-428
51. Targoff I.N. Idiopathic inflammatory myopathy: autoantibody update. Curr. Rheumatol. Rep. 4 (2002) 434-441
52. Mathews M.B., and Bernstein R.M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 304 (1983) 177-179
53. Bernstein R.M., Morgan S.H., Chapman J., et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br. Med. J. (Clin. Res. Ed.) 289 (1984) 151-152
54. Mozaffar T., and Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J. Neurol. Neurosurg. Psychiatry 68 (2000) 472-478
55. Arlet J.B., Dimitri D., Pagnoux C., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul. Disord. 16 (2006) 334-336